deltatrials
Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05430399

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer : A Phase III, Open Label, Randomized Controlled Trial

Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd.

Conditions Breast Neoplasms Locally Advanced or Metastatic Breast Cancer
Interventions docetaxel utidelone
Updated 6 times since 2022 Last updated: Jul 11, 2023 Started: Jun 21, 2022 Primary completion: Jun 1, 2025 Completion: Jun 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Neoplasms and Locally Advanced or Metastatic Breast Cancer and is currently actively recruiting participants. Beijing Biostar Pharmaceuticals Co., Ltd. leads this study, which shows 6 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2022 – ~Feb 2023 · 7 months · monthly snapshotNot Yet Recruiting~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Aug 2023 · 4 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotRecruiting

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  3. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  4. Apr 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  5. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. Jul 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Jun 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Biostar Pharmaceuticals Co., Ltd.
  • Hunan Cancer Hospital
  • Sun Yat-sen University
Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations